Other names
This indicator shows the number and percent of people with diabetes receiving vildagliptin regularly. Regular use was defined as vildagliptin dispensed in three or more quarters in a year.
Understanding variation in dispensing these medicines is important for optimising diabetes care and ensuring that patients receive the most appropriate treatments.
People with diabetes dispensed vildagliptin in three or four quarters in the relevant year
Numerator detail
410325 vildagliptin
410425 & 410426 vildagliptin with metformin hydrochloride
Count of distinct master NHIs identified as having diabetes as per the VDR
Disaggregation
For single map analysis: By year (2018‒22), age group (0‒14 years, 15‒24 years, 25‒44 years, 45‒64 years, 65‒74 years and 75+ years), gender (female and male), ethnic group (Māori, Pacific peoples, Indian and European/other) and Health New Zealand district of domicile.
For PHO analysis: By year (2022), age group (0‒14 years, 15‒24 years, 25‒44 years, 45‒64 years, 65‒74 years and 75+ years), gender (female and male), ethnic group (Māori, Pacific peoples, Indian and European/other), PHO most recently enrolled with (for the relevant year), PHO group (small, medium, medium‒large and large).
Atlas of Healthcare Variation - diabetes domain
The Atlas of Healthcare Variation (Te Tāhū Hauora Health Quality & Safety Commission) displays easy-to-use maps, graphs, tables and commentaries that highlight variations by geographic area in the provision and use of specific health services and health outcomes.
The goal of this Atlas of Healthcare Variation domain is to investigate the quality of care given to people with diabetes. The data is not intended to form a basis for judgement or definitive statements of quality, rather to raise questions about potential areas for quality improvement.